Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital
Description
CONCLUSION: The study identified only 0.33% of events as serious, and 99.67% of the study population recovered from the AEFIs, which reveals that COVISHIELD™ and COVAXIN^(®) have a generally favourable safety profile. However, close monitoring is
